Abstract
Advanced glycation end-products (AGEs) have and important role in the pathophysiology of heart failure (HF) [1]. Some of these products present auto-fluorescent, feature typically used to measure them [2]. Recently, it has been described the characterization of AGEs using mass spectrometry (MS) [3]. Our aim was to evaluate the usefulness of these techniques to measure AGEs in patients with HF. One hundred consecutive patients with HF attending our medical centre were included in the study and clinical and analytical data were obtained (69.7±11.9 years, 34% female, 36% diabetics). Fluorescent AGEs and mass-shift of glycated albumin were respectively measured by fluorescence spectroscopy and MALDI-TOF/MS in the plasma of these patients. Positive association between glycated albumin mass-shift (66,616 ± 32.2 Da ranging 66,565 – 66,686 Da) and plasma levels of fluorescent AGEs (65.5 ± 20.8 a.u. ranging 29.5 - 128.8 a.u.) was observed (p < 0.05). While fluorescent AGEs only measure part of the total glycated modifications, the MS technique allow a global measurement of the glycated state of major circulating proteins. However, the strong correlation between both types of measure, points out that both of them can be used as biomarkers of the glycation state of plasma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
